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Recently we reported the immune-potentiating capacity of a Chlamydia nanovaccine
(PLGA-rMOMP) comprising rMOMP (recombinant major outer membrane protein)
encapsulated in extended-releasing PLGA [poly (D, L-lactide-co-glycolide) (85:15)]
nanoparticles. Here we hypothesized that PLGA-rMOMP would bolster immune-
effector mechanisms to confer protective efficacy in mice against a Chlamydia
muridarum genital challenge and re-challenge. Female BALB/c mice received three
immunizations, either subcutaneously (SC) or intranasally (IN), before receiving an
intravaginal challenge with C. muridarum on day 49 and a re-challenge on day 170.
Both the SC and IN immunization routes protected mice against genital challenge with
enhanced protection after a re-challenge, especially in the SC mice. The nanovaccine
induced robust antigen-specific Th1 (IFN-g, IL-2) and IL-17 cytokines plus CD4+
proliferating T-cells and memory (CD44high CD62Lhigh) and effector (CD44high CD62Llow)
phenotypes in immunized mice. Parallel induction of antigen-specific systemic and
mucosal Th1 (IgG2a, IgG2b), Th2 (IgG1), and IgA antibodies were also noted.
Importantly, immunized mice produced highly functional Th1 avidity and serum
antibodies that neutralized C. muridarum infectivity of McCoy fibroblasts in-vitro that
correlated with their respective protection levels. The SC, rather than the IN immunization
route, triggered higher cellular and humoral immune effectors that improved mice
protection against genital C. muridarum. We report for the first time that the extended-
releasing PLGA 85:15 encapsulated rMOMP nanovaccine confers protective immunity in
mice against genital Chlamydia and advances the potential towards acquiring a nano-
based Chlamydia vaccine.
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Chlamydia trachomatis is an intracellular pathogen and
recognizably the most common agent of bacterial sexually
transmitted diseases globally, with over 100 million new cases
per year (1, 2). Chlamydia causes a wide range of damaging
reproductive, clinical, and immunological sequelae in humans,
especially in females, but there are still no commercial vaccines
for clinical applications. There is a broad consensus that
developing a highly effective Chlamydia vaccine to eradicate
the disease and reduce global infection cases is urgently
warranted. Both attenuated or inactivated whole organisms’
vaccines supposedly can induce adequate protection against
many pathogens since they contain an array of antigens (3).
Unfortunately, some pathogens exercise immune evasiveness
and may require different approaches to deliver their antigens
(3) to induce adequate protection. Nowadays, purified or
recombinant antigens as subunit vaccines are becoming more
desirable, mainly due to their safety (1, 4). For many years, the
major outer membrane protein (MOMP) of Chlamydia have
been promising and remains the highly accepted antigenic
vaccine target (2, 5). However, one reason for the lag in
developing a Chlamydia subunit vaccine, such as MOMP, is
perhaps, the lack of a robust adjuvant-delivery system that can
provide a prolonged targeted-delivery and bolstering of
protective immune responses (6, 7).
Failure to develop vaccine constructs against various human
infectious pathogens has resulted in exploring nanoparticles as
alternative delivery platforms. Biodegradable polymeric
nanoparticles are being explored intensively for delivering
biomolecules (8) such as drugs and vaccines due to their
protective, self-adjuvanting, slow-releasing, and flexibility in the
delivery routes (6, 7, 9–11). Previously, we showed that PLA-PEG
[poly(lactic acid)-poly(ethylene glycol)]-encapsulating M278
(MOMP peptide) triggered robust Chlamydia-specific immune
responses and afforded protection against a homologous genital
challenge in immunized mice (10). We also reported that
recombinant MOMP (rMOMP) encapsulated in PLGA [poly (D,
L-lactide-co-glycolide)] 50:50 nanoparticles potentiated
Chlamydia-specific adaptive immune responses in immunized
mice (12). Recently, we aimed to enhance the immunogenic
potential of rMOMP by its encapsulation in the biodegradable
extended-releasing PLGA 85:15 nanoparticles (PLGA-rMOMP) to
serve as an adjuvant-delivery platform. Evaluation of the new
PLGA-rMOMP nanovaccine revealed that it augmented
endosomal processing, activated and boosted dendritic cells
(DCs) responses, including Th1 cytokines and MHC class II
molecules. We also observed the bio-distribution of PLGA-
rMOMP to lymph nodes of mice by in vivo live imaging and
enhancement of ex vivo T-cells and total IgG antibody immune
responses, which were higher by the subcutaneous (SC) than
intranasal (IN) immunization route (13).
Based on the above findings, we hypothesized that PLGA-
rMOMP would bolster immune-effector mechanisms to confer
protective immunity against a Chlamydia muridarum genital
challenge and re-challenge. Testing of our hypothesis was
conducted in female mice using the SC and IN immunizationFrontiers in Immunology | www.frontiersin.org 2routes. Our results revealed that SC and IN immunization with
PLGA-rMOMP conferred protective immunity against genital
Chlamydia by bolstering systemic and mucosal antigen-specific
cellular and humoral immune effector mechanisms. Here, we
discuss our results, emphasizing the extended-releasing PLGA
85:15 adjuvant-delivery platform for a ChlamydiaMOMP nano-
based vaccine.MATERIALS AND METHODS
Reagents
C. muridarum [strain Nigg II; previously called C. trachomatis
mousepneumonitis (MoPn)biovar] expressedas inclusion forming
units (IFU/mL) was purchased from Virusys Corporation
(Taneytown, MD). The mouse-derived McCoy fibroblasts cell
line and Dulbecco’s Modified Eagle’s Medium (DMEM) with
high glucose and L-Glutamine were both purchased from
American Type Culture Collection (ATCC) (Manassas, VA).
PLGA polymer (85:15 poly-lact ide: poly-glycol ide) ,
dichloromethane (DCM), polyvinyl alcohol (PVA), and
mitomycin-C were purchased from Sigma-Aldrich (St Louis,
MO). ELISA MAX™ Deluxe kit for interferon-gamma (IFN-g),
interleukin-2 (IL-2), and interleukin-17 (IL-17) were purchased
from BioLegend® Inc. (San Diego, CA). RPMI-1640 with
GlutaMax™ and HEPES, heat-inactivated fetal bovine serum
(FBS), ACK lysing solution, and antibiotic-antimycotic were all
purchased from Life Technologies (Grand Island, NY). Anti-CD
90.2 magnetic beads and MACS columns were purchased from
Miltenyi Biotech (Auburn, CA). Cel lTrace™ CFSE
(carboxyfluorescein succinimidyl ester) cell proliferation assay kit
(C34554) and Remel™ PathoDx™ Chlamydia culture
confirmation kit (R62210) were purchased from Thermo Fisher
Scientific (Waltham, MA). The Fc block anti-CD16/32 antibody
(BD:553141), fluorochrome-conjugated antibodies: CD3-APC-
Cy7 (BD:560590), CD4-PerCP-Cy5.5 (BD:550954), CD62L-APC
(BD:553152), CD44-PE (BD:553134), and Opti-EIA sets for
interleukin-10 (IL-10) were obtained from BD-Biosciences (San
Jose, CA). Medroxyprogesterone acetate (Depo-Provera) was
purchased from Pfizer (New York, NY), and cycloheximide was
obtained from EMD Biosciences (La Jolla, CA).
Nanovaccine Formulation
The rMOMP (14) was encapsulated in extended-releasing PLGA
85:15 biodegradable nanoparticles to obtain the PLGA-rMOMP
nanovaccine as reported (13). Briefly, PLGA 85:15 (300 mg) was
emulsified in DCM, followed by the addition of 2 mg of rMOMP,
homogenization, and then the addition of 1% PVA. The resulting
double-emulsion was gently stirred overnight at room
temperature (RT) to evaporate the organic solvent, harvested
by ultracentrifugation, washed, and then lyophilized in the
presence of a 5% trehalose solution. Lyophilized nanoparticles
were stored at −80°C in a sealed container until used.
Mice Immunization
Female BALB/c mice (4-6 weeks-old) were purchased from
Charles River Laboratory (Raleigh, NC) and housed underApril 2021 | Volume 12 | Article 660932
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and provided with food and water ad libitum. Mice were
acclimatized for two-weeks before all experimental procedures as
approved by Alabama State University Institutional Animal Care
and Use Committee (IACUC). Mice used here were a subgroup of
our recently published study (13). Mice were divided into
experimental groups (10 to 11 mice/group) for the immunization
studies and were immunized, as shown in Figure 1. Briefly, two
groups of mice received either three SC or IN immunizations (pre)
at two-week intervalswithPLGA-rMOMP.Eachmouse received50
μg/100 μL SC or 50 μg/20 μL IN (10 μL each nostril) of PLGA-
rMOMPin sterile phosphate-buffered saline (PBS).Mice in the PBS
group were administered SCwith 100 μL of sterile PBS. Two-weeks
following the last immunization (day 42), 5 mice/group were
sacrificed to collect spleen and serum samples for cellular and
humoral immune-effectors analyses, respectively.
C. muridarum Vaginal Challenge and
Re-Challenge
For the challenge study, SC- or IN-immunized mice (6/group)
and PBS (5/group) were each injected SC with 2.5 mg of Depo-
Provera two-weeks after the last immunization and one week
later (day 49) by an intravaginal challenge with 1×105 IFU of C.
muridarum in sucrose-phosphate-glutamic acid (SPG) buffer
(10). For the re-challenge (post) study, the same mice were
injected SC with 2.5 mg of Depo-Provera on day 163 and one
week later (day 170) by an intravaginal re-challenge with 1×105
IFU of C. muridarum. All mice were sacrificed two-weeks
following the re-challenge to collect spleen and serum samples
for cellular and humoral analyses, respectively.
C. muridarum Quantification From
Vaginal Swabs
Vaginal swabs were collected from each mouse at three-day
intervals up to three-weeks after the first C. muridarum challenge
(day 49) and two-weeks after the re-challenge (day 170). All
swabs were collected in SPG buffer and stored at -80°C to
quantify C. muridarum vaginal load (10). Briefly, McCoy cellsFrontiers in Immunology | www.frontiersin.org 3were propagated in DMEM) and seeded at (5×104/well) in 96-
well cell culture plates. Confluent cell monolayers were
inoculated with vaginal swab suspensions containing 0.5 μg/
mL cycloheximide, centrifuged at 750g for 1 h at RT, and then
incubated for 2 h at 37°C in a 5% CO2 humidified atmosphere.
After that, fresh media containing 0.5 μg/mL cycloheximide was
added to cells and incubated for 30 h. Cells were washed, fixed in
95% ethanol, and stained with a FITC-labeled Chlamydia
antibody using the Remel™ PathoDx™ Chlamydia Culture
confirmation kit. All swabs were cultured in duplicates, and 25
fields from each well were captured using an automated Nikon
confocal microscope (Melville, NY).
Antigen-Specific T-Cell Stimulation
Spleens were collected from immunized (day 42) and re-
challenged mice (day 185) for T-cell stimulation as described
(10, 15). Briefly, spleens were pooled per group and kept in
RPMI-1640 supplemented with 10% FBS and antibiotics-
antimycotic. Single-cell suspensions were obtained and filtered
through a 40-μm nylon mesh strainer and washed before red
blood cell lysis using ACK lysing solution. The cells were
incubated with anti-CD 90.2-conjugated magnetic beads, and
total purified T-cells were isolated by positive selection over
MACS columns. Naïve single spleen cell suspensions were
treated with mitomycin-C (25 μg/mL) for 30 min at 37°C in a
5% CO2 humidified atmosphere and used as antigen-presenting
cells (APCs). Purified T-cells (1×106) and APCs (1×106) co-
cultures were stimulated with rMOMP (5 mg/mL) in round
bottom-polypropylene tissue culture tubes and incubated for
48 h at 37°C in a 5% CO2 humidified atmosphere. Cell-free
culture supernatants were collected by centrifugation and stored
at -80°C for cytokines quantification.
Cytokines Quantification
Cytokines (IFN-g, IL-2, IL-10 and IL-17) were quantified in cell-
free culture supernatants as described (7, 10). All samples were
run in triplicates, and experiments were repeated at least
three times.FIGURE 1 | Schematic of mice immunization and challenge studies. Three groups of female BALB/c mice were immunized three times (Days 0, 14 and 28) with
either PBS or with 50 µg of PLGA-rMOMP via the SC or IN routes. Mice from each group were sacrificed on day 42 (pre-challenge sacrifice). The remaining mice
received vaginal challenge with live C. muridarum on day 49 (challenge) and day 170 (re-challenge). Cervico-vaginal swabs were collected at 3-day intervals, and
mice were sacrificed on day 185 (post-challenge sacrifice).April 2021 | Volume 12 | Article 660932
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Effector Phenotypes
Purified T-cells were subjected to CFSE-based proliferation
assay, as previously reported (7, 10). Briefly, purified T-cells
from immunized and re-challenged mice were labeled with CFSE
(5 μM) by incubating for 20 min at 37°C in a 5% CO2 humidified
atmosphere. CFSE labeled T-cells (0.5×106) were co-cultured
with APCs (0.5×106) and stimulated with rMOMP (5 mg/mL) in
round-bottom polypropylene tissue culture tubes and incubated
for 120 h at 37°C. After incubation, the cells were harvested and
stained using CD3-APC-Cy7, CD4-PerCP-Cy5.5, CD62L-APC,
and CD44-PE to evaluate T-cell proliferation and memory
(CD44high CD62Lhigh) and effector (CD44high CD62Llow)
phenotypes. Stained cells were washed, fixed, and data were
acquired on a BD LSR II flow cytometer and analyzed using FCS
Express 6 FLOW (De Novo Software, Pasadena, CA). Gating on
CFSE+ T-cells was used for the selection of CD3+CD4+ T-cell
populations. Histogram fluorescence intensities were used to
quantify the proliferating and resting T-cells amongst the total
CFSE+CD3+CD4+ T-cells.Serum and Mucosal Antibody Isotypes
Pooled sera or vaginal wash samples from each group of mice
were used to quantify rMOMP-specific antibodies IgG isotypes
(IgG2a and IgG2b (Th1) and IgG1 (Th2)) and mucosal IgA as
described (10, 12, 14, 15). Briefly, ELISA plates were coated with
100 μL (1 μg/mL) of purified rMOMP and kept overnight at 4°C.
Plates were washed with PBS-Tween 20 (PBST) and blocked in
3% non-fat dry milk. Samples were serially diluted two-fold,
starting at 1:4000 (serum IgG1), 1:500 (serum IgG2a and IgG2b),
1:25 (mucosal wash IgG1, IgG2a, and IgG2b), and 1:5 (mucosal
wash IgA) to determine the endpoint titers. Antigen-specific
IgG2a and IgG2b (Th1) and IgG1 (Th2) were detected using
isotype-specific HRP-conjugated goat anti-mouse antibodies and
TMB substrate. The endpoint titer was considered the last
sample dilution with readings higher than the mean +5
standard deviations of the negative control serum or vaginal
wash (IgG isotypes) or the mean +3 standard deviations of the
negative control vaginal wash samples (IgA). All samples were
run in triplicates and experiments were repeated at least three
times. The ratios for Th1 and Th2 antibodies were calculated
from the endpoint titers (Table 1) using the following equation:
Ratio =
Th1   (IgG2a   or   IgG2b)
Th2   (IgG1)Frontiers in Immunology | www.frontiersin.org 4Serum Antibody Isotypes Avidity
Serum antibody isotypes avidity index (AI) was determined as
previously described (10, 13). ELISA plates were coated with
purified rMOMP, as described above in the serum and mucosal
antibodies section. Sera were diluted (1:50, 1:100, 1:200 and
1:400) and then added to wells in parallel (2 sets per plate) and
incubated for 2 h at RT. Plates were washed with PBST, and one
set for each serum sample was treated with urea (8M in PBST),
and the other set was treated with PBST for 5 min at RT. After
washing, rMOMP-specific IgG2a and IgG2b (Th1) and IgG1
(Th2) were detected using isotype-specific HRP-conjugated goat
anti-mouse antibodies and TMB substrate. All samples were run
in triplicates, and experiments were repeated at least three times.
The AI was calculated using the following equation:





Neutralization of Chlamydia In Vitro
C. muridarum neutralization by serum from immunized and re-
challenged mice was performed using McCoy cells as previously
described (10). Briefly,McCoy cellswere propagated inDMEMand
seeded (5×104/well) in 96-well flat-bottom cell culture plates. In a
separate 96-well plate, C. muridarum elementary bodies (EBs) at
500 IFU/well were treatedwith optimally diluted serum (1:100) and
incubated for 30min at 37°Cona slowly rocking platform.Treated-
EBs were then added to McCoy cells confluent monolayers and
centrifuged at 750g for 1 h, followed by incubation for 2 h at 37°C in
a 5% CO2 humidified atmosphere. The medium was replaced with
fresh DMEM containing 10% FBS and 0.5 μg/mL cycloheximide
and then incubated for 30 h. Untreated-EBs and naïve serum were,
respectively, used as positive and negative controls. After
incubation, the plates were fixed with 95% ethanol and stained
using the Remel™ PathoDx™Chlamydia culture confirmation kit.
All samples were cultured in triplicates, and three fields from each
wellwere capturedusing anautomatedNikon confocalmicroscope.
Experiments were repeated at least two times.
Statistical Analysis
Data were analyzed by two-way analysis of variance (ANOVA)
followedbyTukey’smultiple comparison test to compare recovered
IFU, cytokines production, and in vitro neutralization between and
within groups. One-way ANOVA followed by Holm-Sidak was
used for mean IFU comparison between groups, and all analyses
were performed using GraphPad Prism 8 (San Diego, CA).
P values ≤ 0.05 were considered statistically significant.TABLE 1 | rMOMP-specific serum antibodies endpoint titers of immunized mice.
Antibodies PBS SC IN
Pre-challenge Post-challenge Pre-challenge Post-challenge Pre-challenge Post-challenge
IgG2a - 1,000 128,000 64,000 - 16,000
IgG2b - - 256,000 128,000 2,000 8,000
IgG1 - - 512,000 128,000 32,000 4,000April 2021 | Volume 12‘-’not detected.| Article 660932
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Immunization With PLGA-rMOMP Protects
Mice Against Genital Chlamydia
We recently reported that PLGA-rMOMP induced heightened
adaptive immune responses in mice immunized via the SC rather
than the IN route (13). Here we investigated the capacity of the
PLGA-rMOMP nanovaccine to confer protective efficacy in mice
against a C. muridarum genital challenge and re-challenge. We
tested the hypothesis that the SC rather than the IN-
immunization route would be more efficacious in protecting
mice against genital Chlamydia. Following three immunizations
with PLGA-rMOMP via the SC or IN routes, mice received an
intravaginal challenge with C. muridarum (1×105 IFU/mouse)
on day 49 to evaluate protection by quantifying chlamydial IFU
from vaginal swabs. SC and IN immunization significantly
protected (P < 0.05 to 0.001) mice against a challenge as
compared to the PBS control mice that consistently had higher
recovered IFU (Figure 2A). Overall, all mice immunized via the
SC route had lower IFU than the IN group even though the
differences did not reach statistical significance (Figure 2B).
Further, we evaluated whether the nanovaccine can elicit
protection against a re-challenge and administered mice an
intravaginal C. muridarum (1×105 IFU/mouse) 120 days after
the first challenge. Both SC and IN immunization significantly
(P < 0.0001) enhanced protection after re-challenge (Figures
2C, D) versus the first challenge (Figures 2A, B) by the lower
recovered IFU, suggesting elicitation of protection facilitated by
the nanovaccine. The recovered IFU from the PBS control mice
markedly reduced on day 12 compared to day 15 for the SC- and
IN-immunized mice (Figure 2C), suggesting possibly an
infection-induced immunity-boosting effect arising from the
first challenge.
Induction of Antigen-Specific Cytokines
From T-Cells After Immunization
and Re-Challenge
Induction of cell-mediated immunity is pivotal in protection
against genital Chlamydia (16). Thus, we assessed T-cell
cytokines that may correlate with the protection of mice
against genital C. muridarum. We quantified Th1 (IFN-g, IL-
2), Th2 (IL-10) and Th17 (IL-17) cytokines secreted by purified
T-cells from mice after PLGA-rMOMP immunization (pre) and
again after challenge and re-challenge (post). As illustrated in
Figure 3A, SC and IN immunized mice (pre) produced ~ 3-fold
significantly higher IFN-g (P < 0.0001) compared to the PBS
controls. Similarly, IFN-g production was higher (P < 0.0001) in
the SC and IN mice (post) relative to the PBS controls. IL-2 was
significantly (P < 0.001) produced by T-cells from immunized
(SC and IN) mice (pre) and by more than a 2-fold increment (P <
0.0001) after re-challenge (post) compared to the PBS mice
(Figure 3B). Though IFN-g and IL-2 secretions were less in
the PBS controls (pre and post), they were increased (P < 0.0001)
after re-challenge (post) (Figures 3A, B). Overall, all mice
produced less IL-10 (pre or post); however, IL-10 was reduced
(P < 0.01) only after re-challenge of the SC mice (Figure 3C),Frontiers in Immunology | www.frontiersin.org 5therefore confirming a predominantly Th1 response. The results
also showed that IL-17, an immunoregulatory cytokine, which is
essential in intracellular pathogen clearance (17) was enhanced
(P < 0.0001) in the SC and IN mice (pre) in comparison to the
PBS control mice, and all groups of mice after re-challenge (post)
as seen in Figure 3D.
Induction of Antigen-Specific CD4+ T-Cell
Proliferation and Memory and Effector
Phenotypes After Immunization
CD4+ T-cell-derived memory and effector phenotypes play




FIGURE 2 | Protection of PLGA-rMOMP-immunized mice against vaginal C.
muridarum challenge and re-challenge. Groups of mice were each immunized
three times at two-week intervals with PLGA-rMOMP via the SC or IN routes.
Each mouse was challenged intravaginally with 1×105 IFU of C. muridarum,
and cervico-vaginal swabs were collected and propagated in McCoy
fibroblasts to quantify the recovered IFU. Each floating bar represents the
minimum and maximum range for IFU counts (IFU/mL) from individual swabs.
The middle line represents the mean (IFU/mL) for each group of mice after
challenge (A) and re-challenge (C). Graph inserts represent IFU/mL (mean ±
SE) calculated for combined days 3 to 15 after challenge (B) and re-challenge
(D); numbers above bars indicate percent (%) reduction in recovered IFU
compared to the PBS control. Statistical analyses were performed using two-
way ANOVA followed by Tukey’s multiple comparisons for IFU/mL (A, C) and
one-way ANOVA followed by Holm-Sidak for the mean IFU/mL (B, D).
Significant differences were considered at ****P < 0.0001, ***P < 0.001,
**P < 0.01 and *P < 0.05. No exclusions were applied for IFU counts.April 2021 | Volume 12 | Article 660932
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rMOMP would promote specific T-cell activation to protect
immunized mice against genital Chlamydia. T-cells were collected
frommice after immunization (pre) and CFSE-labeled. Labeled T-
cells were co-cultured with APCs followed by stimulation with
rMOMP to evaluate T-cell proliferation along with memory and
effector phenotypes employing multi-parameter flow cytometry.
As illustrated in Figure 4A, unstimulated CSFE+CD3+CD4+
T-cells were high in the SC (46.63% (vi)) and IN (46.32% (x))
immunized mice (pre) as compared to the PBS control (43.93%
(ii)). Moreover, there were more proliferating CD4+ T-cells (M1
population) than resting CD4+ T-cells (M2 population) with the
SC mice exhibiting higher proliferating CD4+ T-cells (70.03%
(vi)) as compared to the IN (66.42% (xi)) and PBS control
(66.62% (iii)). Following stimulation of cells with rMOMP an
increase of CFSE+CD3+CD4+ T-cells was seen more in the SC
(51.26%) than the IN (47.78%) and PBS (45.92%) groups,
respectively (Figures 4B (ii), (vi), (x)). Importantly, we
observed an enhancement in the M1 proliferating CD4+ T-cellsFrontiers in Immunology | www.frontiersin.org 6in the immunized SC (74.71%) and IN (69.59%) mice but not
the PBS control (66.17%) (Figures 4B (iii), (vii), (xi)), which
are suggestive of immune memory for antigen recognition.
These results suggest increased in T-cell numbers and
enhanced proliferation of CD4+ T-cells, especially in the SC-
immunized mice.
We also quantified memory (CD44high CD62Lhigh) and
effector (CD44high CD62Llow) phenotypes in unstimulated and
rMOMP-stimulated cells by gating on the CFSE+CD3+CD4+ T-
cell populations. Unstimulated proliferating CD3+CD4+ T-cells
from the SC-immunized mice (pre) differentiated into 19.93%
memory phenotype (CD44+ CD62L+) as compared with 12.95%
and 12.12%, respectively, for the IN and PBS groups (pre)
(Figures 4A (iv), (viii), (xii)), suggesting higher induction of
memory cells via the SC route. Notably, was the marked
enhancement of CD3+CD4+ memory (CD44+ CD62L+) in SC-
mice (30.94%) (Figure 4B (viii)) compared to the IN (14.19%)
and PBS (12.72%) mice (Figures 4B (xii), (iv)). After rMOMP
stimulation, the effector T-cell phenotype (CD44+ CD62L-)A B
C D
FIGURE 3 | Enhanced production of Chlamydia-specific Th1, Th2, and Th17 cytokines by T-cells from PLGA-rMOMP-immunized and challenged mice.
Immunomagnetic purified splenic T-cells (1×106) were co-cultured with mitomycin-C treated APCs (1×106) and stimulated with rMOMP (5 mg/mL) for 48 h at 37°C in
a 5% CO2 humidified atmosphere. Cell-free supernatants were collected by centrifugation and used for quantification of cytokines; IFN-g (Th1) (A), IL-2 (Th1) (B), IL-
10 (Th2) (C), and IL-17 (Th17) (D) using cytokine specific ELISAs. Immunized mice (pre); immunized-challenged and re-challenged mice (post). Each bar represents
the mean ± standard deviation (SD) of triplicates from each sample. Statistical analyses were performed using two-way ANOVA followed by Tukey’s multiple
comparisons and significant differences were considered at ****P < 0.0001, ***P < 0.001, **P < 0.01 and *P < 0.05.April 2021 | Volume 12 | Article 660932
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FIGURE 4 | Chlamydia-specific T-cell proliferation and memory and effector T-cells in PLGA-rMOMP immunized and challenged mice. Purified T-cells (1×106)
labeled with fluorescent CFSE dye were co-cultured with mitomycin-C treated APCs (1×106) and stimulated with rMOMP (5 mg/mL) for 120 h at 37°C in a 5% CO2
humidified atmosphere. Co-cultures were centrifuged, and cells were stained with fluorochrome-labeled specific antibodies for CD3, CD4, CD44 and CD62L surface
markers. Cells were acquired on a flow cytometer and analyzed by gating on CD3+ T-cells with secondary gating on CFSE+CD3+CD4+ T-cells for proliferating
memory (CD44+ CD62L+) and effector (CD44+ CD62L-) T-cell phenotypes. Immunized mice (pre), unstimulated (A) and, rMOMP stimulation (B). Proliferating T-cells
(M1) and non-proliferating T-cells (M2).Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6609327
Sahu et al. Chlamydial Nano-Encapsulated Vaccine Protective Immunityincreased in both the SC (21.18%) and IN (23.20%), compared
to the PBS (10.66%) mice (Figures 4B (viii), (xii), (iv)), which
may be attributed to immunological memory induced
by the nanovaccine. Collectively, the SC rather than the
IN route elicited higher cellular-immune responses,
thereby correlating with their higher protection against
genital Chlamydia.
Induction of Antigen-Specific Systemic
and Mucosal Antibody Immune Responses
After Immunization and Re-Challenge
The humoral arm of adaptive immunity also plays a significant
role in protective immunity against Chlamydia (1). The
protection afforded by PLGA-rMOMP in immunized mice
after the first challenge and re-challenge led us to investigate
antigen-specific systemic and mucosal antibodies that may
correlate with protection. Sera collected after immunization
(pre) and re-challenge (post) of mice were used to quantify
rMOMP-specific antibody isotypes by ELISA. In general, SC
immunization induced enhanced antigen-specific Th1 (IgG2a
and IgG2b) and Th2 (IgG1) antibodies and their specific titers
before (pre) and after re-challenge (post) as compared with IN
immunization (Figures 5A–F and Table 1). Re-challenge (post)
of the SC mice diminished Th1 and Th2 antibodies compared to
those after immunization (pre). Conversely, the IN mice
produced enhanced Th1 and not Th2 antibodies (Figures 5B,
D, F and Table 1). The PBS control (pre) mice did not produce
any antigen-specific antibodies (Figures 5A, C, E and Table 1).
Based on the enhanced antibody responses, especially in the
SC mice, we next examined the IgG2b/IgG1 Th1/Th2 antibody
ratios to discern the impact of the immunization routes on
humoral protective immunity. As depicted in Figure 5G, the
SC, and especially the IN immunization routes triggered a
predominant Th2 response (pre). Interestingly, although SC
mice produced higher Th1 and Th2 antibodies, a bias towards
a predominant Th1 response (post) occurred more in the IN
mice by the higher Th1/Th2 ratio. The IgG2a/IgG1 Th1/Th2
ratios were not calculated because of no IgG2a endpoint titer in
the IN mice (pre). Overall, these results reveal insights into
possible Th1 and Th2 antibody-protective immune effectors
elicited by PLGA-rMOMP with a predominant Th2 response
(pre) after immunization and then mixed Th1/Th2 (SC mice)
and Th1 (IN mice) responses after a chlamydial genital re-
challenge (post).
We also quantified rMOMP-specific mucosal antibodies in
vaginal washes collected from immunized mice (pre). SC
immunization induced higher Th2 (IgG1) and lower Th1
(IgG2a and IgG2b) antibody titers, whereas IN immunization
only induced a minimal Th2 (IgG1) antibody response (Figures
6A–C and Table 2). Of no surprise, IN immunization elicited a
higher mucosal IgA antibody response and titer than the SC
immunization (Figure 6D, Table 2). The PBS control mice did
not produce mucosal antibodies (Figures 6A–D. These results
indicate that the SC delivery route elicited higher antigen-specific
mucosal antibodies (Th1 and Th2), contrastingly to the
predominant IgA antibody produced via the IN route.Frontiers in Immunology | www.frontiersin.org 8Avidity-Index (AI) of Antigen-Specific
Serum Antibody Isotypes After
Immunization and Re-Challenge
The binding strength of a specific antibody to a selective epitope
enhances the functionality of antibody immune responses.
Chlamydial MOMP contains antigenic epitopes that are
important in inducing specific antibodies (18). To determine
the isotype differences in functional Th1 (IgG2a and IgG2b) and
Th2 (IgG1) antibodies induced by immunization (pre) and re-
challenge (post), we used urea as a chaotropic agent for the
elution of low-avidity serum antibodies and calculated the AI
(%). Our results demonstrate that the SC mice (pre and post)
produced more highly functional avidity antibodies than the IN
mice (Figure 7). The functional avidity antibodies were in the
order of magnitude IgG2b (Figure 7C), IgG2a (Figure 7A), and
then IgG1 (Figure 7E). Following a re-challenge (post) of the SC
mice, the functional IgG2b and IgG2a (Figures 7D, B) avidity
antibodies improved compared to a slight increase in IgG1
(Figure 7F). On the other hand, the IN-immunized mice (pre)
selectively produced functional IgG2b avidity antibodies, which
improved after re-challenge (post) (Figure 7D). Interestingly, a
re-challenge of the IN mice (post) also heightened the
functionality of IgG2a (Figure 7B) but not of IgG1
(Figure 7F) avidity antibodies. Re-challenging the PBS control
(post) triggered only functional IgG2a avidity antibodies, albeit
lower than that induced by the SC and IN mice (Figure 7B). The
PBS control mice (pre) did not produce antigen-specific
antibodies (endpoint titers in Table 1) to calculate the avidity
index (Figures 7A, C, E). Overall, the data shows that the
production of antigen-specific functional avidity antibodies is
dependent on the delivery route, given the heightened functional
Th1 than Th2 avidity antibodies induced in SC mice.
Immunization and Re-Challenge of Mice
Induced Serum Antibodies That
Neutralized Chlamydia Cellular
Infectivity In Vitro
Neutralizing antibodies play an essential role in Chlamydia
infection by binding on the EBs surface. Therefore, we assessed
the serum antibody-mediated neutralization of chlamydial EBs
in vitro, using immune (pre) and re-challenge (post) sera from
mice. EBs pre-incubated with sera) were added to McCoy
fibroblasts and incubated for 30 h to assess infectivity by
quantifying the IFU. The results in Figure 8A demonstrate
that the SC- or IN-immunized mice (pre) produced antibodies
that neutralized chlamydial EBs infectivity. However, the
antibodies produced after re-challenge in the SC mice (post)
were more potent in neutralizing EBs (P < 0.001) than those of
the IN and PBS groups (post). Of significance, re-challenge
(post) significantly (P < 0.05) enhanced the serum-neutralizing
antibodies in the SC but not the IN mice.
Further analysis showed that sera from the SC- or IN-
immunized mice (pre) neutralized EBs by 40% and 35%,
respectively, relative to the PBS mice (pre) (Figure 8B).
Moreover, sera obtained from the SC mice after re-challenge
(post) markedly neutralized EBs by 91% compared to 56% for theApril 2021 | Volume 12 | Article 660932





FIGURE 5 | PLGA-rMOMP immunization via the SC route induced enhanced antigen-specific serum antibody isotypes. Groups of mice were immunized three-times
at two-week intervals with either PBS or PLGA-rMOMP via the SC or IN routes. Each mouse was then challenged intravaginally with 1×105 IFU of C. muridarum, and
pooled sera per group were used to quantify rMOMP-specific antibody isotypes by ELISAs. Immunized mice (pre) sacrificed groups; IgG2a (A), IgG2b (C), IgG1 (E),
and immunized-challenge and re-challenge (post) groups; IgG2a (B), IgG2b (D), IgG1 (F). Sera were diluted at a two-fold serial dilution to determine the endpoint
antibody isotype titers. Pre and post Th1/Th2 ratio (G) for SC and IN groups. Each data point represents the mean ± SD of triplicates from each sample.Frontiers in Immunology | www.frontiersin.org April 2021 | Volume 12 | Article 6609329
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results demonstrate that SC and IN immunization, especially the
SC, stimulated superior neutralizing antibodies that effectively
reduced Chlamydia cellular infectivity.DISCUSSION
Developing vaccines is a critical process with stringent provisions
that the vaccine must stimulate robust immune responses, above
those of natural infections, to prevent primary and secondary
infections (2, 19). Notwithstanding, there are significant hurdlesFrontiers in Immunology | www.frontiersin.org 10with subunit vaccines, including premature degradation, efficient
delivery system, optimal doses to induce adequate immune
responses, and an adjuvant to induce stronger immune
responses (20). Given some of the hurdles mentioned above,
there has been an increasingly optimistic approach with a
different paradigm employing nanoparticles as alternative
delivery systems for subunit vaccines. Perhaps this is due to
the flexibility of the nanoparticle-based vaccine formulations for
enhanced delivery, which may be passive by encapsulating or
targeted by adsorbing on the surface of nanoparticles (8).
Besides, employing the nanoparticle-delivery system for
encapsulating antigens affords stability and protection from
premature degradation and the direct intracellular delivery to
APCs (20). Accordingly, this approach, employing biodegradable
nanoparticles as subunit vaccine delivery systems, has been
reported recently for cancer (21, 22) and microbial diseases (4,
20). Since biodegradable nanoparticles undergo degradation by
either hydrolysis or enzymatic processes, they can provide a
sustained-release of antigens over a prolonged time. Hence, a
smaller dose of the released antigen from degrading
nanoparticles is potent to stimulate robust immune responses
due to delivery efficiency at target sites (8). Along with antigenA B
C D
FIGURE 6 | Production of antigen-specific mucosal antibodies in immunized mice. Groups of mice were immunized three times at two-week intervals with either
PBS or PLGA-rMOMP via the SC or IN routes. Pooled mucosal washes per group were diluted at a two-fold serial dilution to determine by ELISA the endpoint
rMOMP-specific antibody isotype titers; IgG2a (A), IgG2b (B), IgG1 (C), IgA (D). Each data point represents the mean ± SD of triplicates from each sample.TABLE 2 | Antigen specific mucosal-antibodies endpoint titers of immunized mice.
Antibodies PBS SC IN
IgG2a – 25 –
IgG2b – 100 –
IgG1 – 200 50
IgA – 5 320‘-’not detected.April 2021 | Volume 12 | Article 660932
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(23–27), though the mechanism of adjuvanticity is not well-
understood (28, 29).
Amongst the family of biodegradable nanoparticles, PLGA
polymers are receiving much scrutiny as delivery platforms for
antigens due to their safety, routes of administration, FDA
approved, and potentiating properties (12, 13, 30–33).
Numerous studies have shown that the PLGA delivery-systemFrontiers in Immunology | www.frontiersin.org 11can dramatically enhance innate and adaptive immune responses
for encapsulated antigens (12, 13, 30, 32, 34–36). Recently,
Khademi et al. demonstrated a Mycobacterium tuberculosis
subunit vaccine formulated with the PLGA: DDA hybrid
nanoparticles induced Th1 immune responses (IFN-g and
IgG2a) (37). Similarly, Kabiri and colleagues observed that
PLGA delivery of the Human T-cell leukemia virus antigenic
epitopes triggered a predominant Th1 (IFN-g and IgG2a) overBA
DC
FE
FIGURE 7 | Avidity index of antigen-specific serum IgG2a, IgG2b and IgG1 isotype antibodies. Groups of mice were immunized three times at two-week intervals
with PBS or PLGA-rMOMP via the SC or IN routes. Each mouse was challenge and re-challenge intravaginally with 1×105 IFU of C. muridarum. Avidity-ELISAs were
conducted using pooled sera from immunized (pre) and immunized-re-challenge (post) mice to determine the avidity index (%) for rMOMP-specific IgG2a (A), IgG2b
(C), IgG1 (E) antibodies (pre), and IgG2a (B), IgG2b (D), IgG1 (F) antibodies (post). Each data point represents the mean ± SD of triplicates from each sample. The
PBS control mice (pre) did not produce antigen-specific antibodies to calculate the avidity index (A, C, E).April 2021 | Volume 12 | Article 660932
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the mucosal and systemic routes (38). As seen, these studies
reinforce the notion that the PLGA delivery system enhances
immune responses in favor of encapsulated antigens.
Chlamydia infections can lead to reproductive morbidities
that arise from severe inflammation, especially at the later stages
(39), when antibiotics therapy has reduced efficacy.
Notwithstanding, after over 70 years of enduring efforts, an
FDA-approved chlamydial vaccine remains an elusive goal (5).
Chlamydial recombinant subunit vaccines are currently the focus
of vaccine development, with safety and efficiency being
foremost, given the exacerbated diseases produced by whole
organism-based vaccines (20). The current study proves that
immunity elicited by the extended-releasing PLGA-rMOMP
nanovaccine can protect against a genital challenge and re-
challenge in the mouse model.
Our results demonstrate that irrespective of the PLGA-
rMOMP immunization route (SC or IN), mice were
significantly protected against a C. muridarum intravaginal
challenge compared to the PBS controls in terms of their lower
IFU. SC immunization afforded better protection after the first C.
muridarum challenge evidently by the lower IFU in all mice
conversely to the higher and varying IFU in the IN-immunized
mice. The variability in Chlamydia IFU observed between mice
on pre-selected days after the C. muridarum challenge has been
reported (10, 40). However, we did observe an earlier IFU
reduction in the PBS controls after re-challenge (day 12),
suggesting a possible infection-induced immunity booster effect
from the first challenge to afford their early reduced bacterial
burden. Enhanced protection against C. muridarum re-challenge
in the SC- and IN- immunized mice compared to the PBS control
is a strong implication of the extended-releasing nanovaccine
coordinated with an infection-induced immunity-boosting effect,
which facilitated enhanced protection of mice against re-
challenge. In conjunction with our observations, otherFrontiers in Immunology | www.frontiersin.org 12investigators have reported mice protection against a
Chlamydia re-infection, but for a lesser duration of only 28
days (41) and 92 days (42) between the first and
second infections.
Here our results suggest that T-cells are essential mediators of
protective immunity ensuing from the immunization of mice
with PLGA-rMOMP for adequate protection against a C.
muridarum challenge and re-challenge. The heightened
protective chlamydial-specific Th1 cytokines (IFN-g and IL-2)
and CD4+ memory and effector T-cells produced after
immunization of mice (SC and IN) corroborate reports of Th1
immune effectors that can clear a C. muridarum vaginal
challenge (10, 40). Indeed, the protective role of Th1 cytokines
has directly been correlated with IFN-g-mediated Chlamydia
killing by activating T-cells (43, 44). In line with our observation,
CD4+ T-cells driven-immune responses with pronounced IFN-g
production are reportedly adequate for protection against C.
muridarum infections in the genital tract (45–47). More
importantly and from a translational perspective, our results
are aligned with a study conducted with C. trachomatis-infected
women that showed a Chlamydia-specific CD4+ derived IFN-g
response is protective against re-infection and is a crucial
adaptive immunity component (48).
Even though IL-2 has no direct effector function, it is directly
associated with effector T-cell proliferation, consistent with
previous findings of CD4+ effector T-cells expansion (10, 49).
Studies have shown that the additional IL-2 can boost the
antigen-specific T-cell responses, proliferation, and
differentiation process (50). The increase in IL-2 production in
the current study may be associated with PLGA-rMOMP
inducing rMOMP-specific CD4+ T-cells proliferation to
differentiate into memory (CD44high CD62Lhigh) and effector
(CD44high CD62Llow) phenotypes. The expansion of the CD4+ T-
cell phenotypes indicates that the effective delivery of the
nanovaccine within APCs and presentation via MHC II (51)BA
FIGURE 8 | Serum-mediated neutralization of Chlamydia infectivity of mouse fibroblasts. McCoy fibroblasts were infected with sera-C. muridarum inoculum in
triplicates in 96-well plates and incubated for 30 h. Cells were fixed and stained, and IFU images were captured by immunofluorescence microscopy. Results are
shown as C. muridarum (IFU/mL) detected in cells exposed to pooled sera from groups of mice. Each symbol represents the IFU counts (mean ± SD) of three fields
and three different wells from immunized (pre) and immunized re-challenge (post) groups of mice. Horizontal red line represents the mean IFU/mL per group (A).
The % neutralization (mean ± SE) of C. muridarum EBs in fibroblasts in the presence of serum antibodies (B). Statistical analyses were performed using two-way
ANOVA followed by Tukey’s multiple comparisons and significant differences were considered at ***P < 0.001and *P < 0.05.April 2021 | Volume 12 | Article 660932
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immunized mice. Confirming this observation, we recently
reported the upregulation of Chlamydia-specific memory and
effector cells mediated by MHC II and CD4+ T-cells in mice
immunized with PLA-PEG encapsulating the M278 peptide from
MOMP or with PLGA-rMOMP (7, 10, 13). Another observation
worth mentioning is the upregulated IL-17 in immunized mice,
both pre- and post-challenge. This finding is supportive of the
immunoregulatory role of IL-17 inhost defense against intracellular
pathogens (17, 52, 53), and presumably,Chlamydia, as shown here.
Reportedly, SC immunization of mice with CTH522/CAF01
induced IFN-g and IL-17, which were associated with protection
against chlamydial genital infection and re-infection (42). Others
have shown thatmucosal immunization ofmice withMOMPVS2/
4-CTA1-DD reduced chlamydial genital infection and up-
regulated IFN-g and IL-17 producing T cells (54). Moore and
colleagues demonstrated that IL-17 promoting Th17
differentiation occurs under the influence of a pro-inflammatory
cytokine environment that was reduced in IL-6-deficient DCs (53).
Thus, IL-6 is a crucial regulator of Th17 differentiation, which
accentuates our previous observations, whereby DCs produced
elevated levels of IL-6 when stimulated by rMOMP or its peptide
either alone or encapsulated (7, 13).
Although less credence is generally ascribed to the role of
antibodies against Chlamydia clearance, many studies suggest that
mobilization of both humoral and cellular immune responses are
required (47, 55, 56). The abundant expression of MOMP in the
biphasic lifecycle of Chlamydia is strong evidence for its induction
of protective serum neutralizing antibodies (57). Morrison et al.
established using B-cell knockout mice that B-cells and CD4+ T-
cells are necessary for protective immunity in the case ofChlamydia
re-infection (47). Li et al. demonstrated that B-cells play a distinct
role by enhancingChlamydia-specific CD4+T-cells primingwithin
lymph nodes leading to robust production of cytokines (IFN-g and
IL-17) and long-term memory formation (58). Here in this study,
concurrent induction of cellular and humoral immune-effectors
may have provided the requisites protective immunity against
genital Chlamydia in mice. Significantly higher production of
systemic Th1 (IgG2a and IgG2b) and Th2 (IgG1) Chlamydia-
specific antibodies and their titers were more notable in the SC
rather than the IN delivery of the nanovaccine. Consistent with our
results is evidence supporting that PLGA delivery of antigens
induces higher production of antibodies via the SC- than the IN-
immunization route (9, 59).Not surprisingwas the high production
of mucosal IgA only in the IN mice. It could be conjectured that
humoral protective immunemechanisms differ in the IN versus the
SC mice. For example, the differences could be due to functionally
different antibodies like mucosal IgA in the IN and more systemic
and mucosal Th1 and Th2 antibodies in the SC mice. Reportedly,
high levels of IgG antibodies and T-cells can facilitate early control
of chlamydial infections, but the presence of antigen-specific IgA
further accelerates the clearance (60). Other investigators also show
IgA’s contributory role in protective immunity and efficacy against
Chlamydia infection in mice (54, 61, 62).
The participation of memory B-cells in humoral protective
immunity requires an antigen-specific affinity for re-stimulationFrontiers in Immunology | www.frontiersin.org 13to proliferate and differentiate into antibody-producing plasma
cells (63). It is well-known that repeated exposure to antigen
leads to elevated antibody titers and functionality due to somatic
hypermutations and antigen selection in germinal centers where
antibody avidity maturation occurs (64). Extended-release of
antigens resembles a persistence infection, which drives memory
B-cells to re-program for efficient binding and inactivation of the
pathogen (65). Serum-neutralization of Chlamydia infectivity in
vitro is employed frequently as a predictor of the vaccination
effect (10, 66) since this process is mediated by functional
antibodies induced by immunization. Production of functional
antibodies leads to memory B-cells formation and correlates
directly with a high avidity-index. Our results show that highly
functional rMOMP-specific isotype avidity antibody polarization
(Th1 or Th2) may have contributed to neutralizing Chlamydia
infectivity in the SC and IN mice. SC immunization triggered
superior Th1 and Th2 functional antibodies but unequivocally
more highly functional Th1 (IgG2a and IgG2b) avidity isotypes
whose functionality improved after re-challenge. High rMOMP-
specific functional avidity antibodies, especially in the SC-
immunized mice, may, in part, explain their better protective
efficacy. Previously, we showed that the functionality of
antibodies becomes stronger with Chlamydia challenge in mice
immunized SC with a MOMP peptide (M278) encapsulated
within PLA-PEG nanoparticles (10).
In conclusion, an advantage of biodegradable nanoparticles is
the versatility of the delivery routes for delivering subunit vaccines
against mucosal pathogens, as highlighted here with PLGA-
rMOMP. Parallel induction of cellular and humoral immune-
effectors by the nanovaccine plus an infection-induced immunity-
boosting effect orchestrated by immunological memory involving
T- andB-cellsmost likely afforded protective immunity against aC.
muridarum re-challenge. SC and IN immunization bolstered a
dominant Th1 cellular with mixed Th1/Th2 antibody responses,
functional Th1 avidity, and neutralizing antibodies. However, the
SC route was more efficient in eliciting superior immune-effectors
for better protection. PLGA 85:15 delivery of rMOMP protected
mice against genital Chlamydia facilitated by the extended-release
of rMOMP for continuous stimulation of immune cells along with
an infection-induced immunity booster after re-challenge. This
study is the first to report the protective efficacy conferred by
extended-releasing PLGA 85:15 encapsulation of rMOMP against
genital Chlamydia in the mouse model.DATA AVAILABILITY STATEMENT
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